Nektar Therapeutics Income Taxes Paid
Nektar Therapeutics (NKTR) reported Income Taxes Paid of -$195.00 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-13.
Financial Statements › Cash Flow › Other Cash Flow Items
us-gaap:IncomeTaxesPaidNet · last filed 2026-03-13
- Nektar Therapeutics income taxes paid, net for the quarter ending 2023-12-31 was $0.00, a 100.00% decline year-over-year.
- Nektar Therapeutics income taxes paid, net for the quarter ending 2023-09-30 was $0.00.
- Nektar Therapeutics income taxes paid, net for the quarter ending 2022-12-31 was $272.00K.
- Nektar Therapeutics income taxes paid, net for the quarter ending 2022-09-30 was -$85.00K.
- Nektar Therapeutics income taxes paid, net for fiscal 2025 was -$195.00K, a 356.58% decline from fiscal 2024.
- Nektar Therapeutics income taxes paid, net for fiscal 2024 was $76.00K, a 97.14% decline from fiscal 2023.
- Nektar Therapeutics income taxes paid, net for fiscal 2023 was $2.66M, a 876.47% increase from fiscal 2022.
- Nektar Therapeutics income taxes paid, net for fiscal 2022 was $272.00K, a 16.31% decline from fiscal 2021.
| Period end | Income Taxes Paid, Net 3 month | Income Taxes Paid, Net 6 month | Income Taxes Paid, Net 9 month | Income Taxes Paid, Net 12 month |
|---|---|---|---|---|
| 2025-12-31 | -$195.00K 10-K · filed 2026-03-13 | |||
| 2024-12-31 | $76.00K 10-K · filed 2026-03-13 | |||
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-14 | $0.00 derived: sum of 2 quarters · filed 2025-03-14 | $2.66M 10-K · filed 2025-03-14 | |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-08 | $2.66M 10-Q · filed 2024-11-08 | ||
| 2023-06-30 | $2.66M 10-Q · filed 2023-08-09 | |||
| 2022-12-31 | $272.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-05 | $187.00K derived: sum of 2 quarters · filed 2024-03-05 | $272.00K 10-K · filed 2024-03-05 | |
| 2022-09-30 | -$85.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08 | $0.00 10-Q · filed 2023-11-08 | ||
| 2022-06-30 | $85.00K 10-Q · filed 2023-08-09 | |||
| 2021-12-31 | $325.00K 10-K · filed 2024-03-05 | |||
| 2020-12-31 | $539.00K 10-K · filed 2023-02-28 | |||
| 2019-12-31 | $555.00K 10-K · filed 2022-03-01 | |||
| 2018-12-31 | $618.00K 10-K · filed 2021-02-26 | |||
| 2017-12-31 | $556.00K 10-K · filed 2020-02-28 | |||
| 2016-12-31 | $757.00K 10-K · filed 2019-03-01 | |||
| 2015-12-31 | $860.00K 10-K · filed 2018-03-01 | |||
| 2014-12-31 | $964.00K 10-K · filed 2017-03-01 | |||
| 2013-12-31 | $1.01M 10-K · filed 2016-02-29 | |||
| 2012-12-31 | $1.02M 10-K · filed 2015-02-26 | |||
| 2011-12-31 | $957.00K 10-K · filed 2014-02-27 | |||
| 2010-12-31 | $407.00K 10-K · filed 2013-03-01 | |||
| 2009-12-31 | $743.00K 10-K · filed 2012-02-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |